NKTX Stock Price, Nkarta Inc Quote, Chart

Market Summary

USD6.51-0.31

Market Closed

-4.55%

NKTX Stock Price

View Fullscreen

NKTX RSI Chart

NKTX Valuation

Market Cap

458.7M

Price/Earnings (Trailing)

-3.95

Price/Sales (Trailing)

33.03

Price/Free Cashflow

-3.91

NKTX Price/Sales (Trailing)

NKTX Profitability

Return on Equity

-24.53%

Return on Assets

-20.14%

Free Cashflow Yield

-25.59%

NKTX Fundamentals

NKTX Revenue

Revenue (TTM)

13.9M

Rev. Growth (Yr)

-6.32%

Rev. Growth (Qtr)

-6.08%

NKTX Earnings

Earnings (TTM)

-116.2M

Earnings Growth (Yr)

4.21%

Earnings Growth (Qtr)

-6.36%

Breaking Down NKTX Revenue

Last 7 days

4.2%

Last 30 days

-17.2%

Last 90 days

-39.9%

Trailing 12 Months

44.7%

How does NKTX drawdown profile look like?

NKTX Financial Health

Current Ratio

19.95

NKTX Investor Care

Shares Dilution (1Y)

44.00%

Diluted EPS (TTM)

-2.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	13.9M	0	0	0
2023	8.9M	11.8M	13.5M	14.1M
2022	372.0K	954.0K	2.8M	5.6M
2021	327.3K	341.5K	355.8K	370.0K
2020	306.3K	308.5K	310.8K	313.0K
2019	0	0	0	304.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Nkarta Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 27, 2024	george simeon	bought	4,516,590	10.00	451,659	-
Mar 27, 2024	ra capital management, l.p.	bought	30,000,000	10.00	3,000,000	-
Mar 27, 2024	george simeon	bought	15,483,400	10.00	1,548,340	-
Mar 04, 2024	hastings paul j	back to issuer	-1,834,770	13.33	-137,642	chief executive officer
Mar 01, 2024	brandenberger ralph	acquired	26,308	3.89	6,763	chief technical officer
Mar 01, 2024	brandenberger ralph	sold	-104,671	12.51	-8,367	chief technical officer
Mar 01, 2024	hastings paul j	back to issuer	-160,654	13.00	-12,358	chief executive officer
Feb 12, 2024	trager james	sold	-49,716	12.00	-4,143	chief scientific officer
Jan 16, 2024	hager alicia j.	sold	-39,802	8.74	-4,554	chief legal officer
Jan 16, 2024	hastings paul j	sold	-84,751	8.74	-9,697	chief executive officer

Which funds bought or sold NKTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.92	14.00	32,862	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-16.55	353,987	1,319,110	-%
May 15, 2024	SUPERSTRING CAPITAL MANAGEMENT LP	added	242	10,562,500	12,855,200	8.50%
May 15, 2024	T. Rowe Price Investment Management, Inc.	added	192	11,597,000	14,652,000	0.01%
May 15, 2024	EcoR1 Capital, LLC	new	-	21,620,000	21,620,000	0.55%
May 15, 2024	Parkman Healthcare Partners LLC	new	-	2,724,420	2,724,420	0.33%
May 15, 2024	Samsara BioCapital, LLC	added	31.38	21,803,400	40,732,500	6.30%
May 15, 2024	Cormorant Asset Management, LP	new	-	14,593,500	14,593,500	0.64%
May 15, 2024	Schonfeld Strategic Advisors LLC	new	-	4,325,080	4,325,080	0.03%
May 15, 2024	Octagon Capital Advisors LP	new	-	2,594,400	2,594,400	0.31%

Are Funds Buying or Selling NKTX?

Are funds buying NKTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NKTX

No. of Funds

Unveiling Nkarta Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	blackrock inc.	4.0%	2,825,506	SC 13G/A
Mar 29, 2024	samsara biocapital, l.p.	5.4%	3,768,035	SC 13D/A
Mar 29, 2024	ra capital management, l.p.	18.9%	13,848,371	SC 13D/A
Mar 28, 2024	new enterprise associates 15, l.p.	5.1%	3,568,781	SC 13D/A
Mar 28, 2024	gsk plc	4.5%	3,150,732	SC 13D/A
Feb 09, 2024	lsp 6 holding c.v.	5.8%	2,836,539	SC 13D/A
Feb 07, 2024	adage capital partners gp, l.l.c.	7.03%	3,450,000	SC 13G/A
Jan 31, 2024	blackrock inc.	5.3%	2,599,201	SC 13G/A
Jan 18, 2024	boxer capital, llc	9.0%	4,407,350	SC 13G
Nov 13, 2023	t. rowe price investment management, inc.	0.8%	430,350	SC 13G/A

Recent SEC filings of Nkarta Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 15, 2024	PRE 14A	PRE 14A
Apr 05, 2024	SC 13G/A	Major Ownership Report
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	SC 13D/A	13D - Major Acquisition
Mar 29, 2024	SC 13D/A	13D - Major Acquisition

Peers (Alternatives to Nkarta Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Nkarta Inc News

Latest updates

Nkarta Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	-6.1%	3,246	3,456	3,616	3,570	3,465	2,890	1,900	686	112	75.00	81.00	104	110	158	206	27.00	124	-	-	-
Operating Expenses	5.1%	32,762	31,185	29,294	36,858	34,313	34,983	30,262	27,612	26,098	22,887	22,428	21,634	19,481	17,999	13,746	10,355	9,408	-	5,909	4,673
S&GA Expenses	-100.0%	-	7,863	7,100	11,736	8,178	8,139	6,827	6,563	6,530	5,586	5,812	5,677	5,942	6,729	3,918	2,493	2,148	-	1,289	1,052
R&D Expenses	8.2%	25,237	23,322	22,194	25,122	26,135	26,845	23,435	21,049	19,568	17,301	16,616	15,957	13,539	11,270	9,828	7,862	7,260	-	4,620	3,621
Net Income	-6.4%	-29,518	-27,754	-25,645	-33,287	-30,815	-32,582	-28,345	-26,923	-25,987	-22,814	-22,353	-21,535	-19,373	-17,897	-13,693	-51,065	-8,706	-10,487	-2,668	-4,838
Net Income Margin	-0.5%	-8.37*	-8.33*	-9.03*	-10.57*	-13.27*	-20.37*	-37.53*	-102.81*	-249.16*	-232.64*	-228.13*	-212.29*	-311.77*	-	-	-	-	-	-	-
Free Cashflow	4.9%	-28,681	-30,161	-26,464	-32,101	-25,581	-42,369	-22,471	-19,243	-20,028	-18,665	-19,777	-18,830	-15,680	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	52.3%	577	379	406	429	458	473	504	504	306	274	292	309	326	338	352	44.00	48.00
Current Assets	75.0%	443	253	281	287	332	361	401	417	223	246	265	284	302	319	333	22.00	37.00
Cash Equivalents	706.3%	250	31.00	38.00	29.00	54.00	37.00	40.00	132	42.00	61.00	96.00	24.00	63.00	97.00	189	18.00	21.00
Net PPE	-1.0%	79.00	79.00	78.00	76.00	70.00	62.00	30.00	17.00	14.00	13.00	14.00	11.00	10.00	9.00	9.00	8.00	3.00
Liabilities	-2.2%	103	106	109	111	112	101	105	83.00	78.00	23.00	22.00	21.00	20.00	16.00	17.00	68.00	14.00
Current Liabilities	-4.9%	22.00	23.00	26.00	27.00	26.00	22.00	26.00	13.00	11.00	13.00	12.00	10.00	9.00	9.00	10.00	60.00	8.00
Shareholder's Equity	73.3%	474	273	297	318	347	372	399	421	229	251	270	288	306	321	335	-	-
Retained Earnings	-6.8%	-464	-435	-407	-382	-348	-317	-285	-257	-230	-204	-181	-158	-137	-118	-100	-86.43	-26.66
Additional Paid-In Capital	32.5%	939	709	705	701	696	691	686	679	459	455	451	447	443	439	435	3.00	1.00
Shares Outstanding	0.5%	49.00	49.00	49.00	49.00	49.00	49.00	49.00	38.00	33.00	33.00	33.00	33.00	-	-	-	-	-
Float	-	-	-	-	38.00	-	-	-	346	-	-	-	441	-	-	-	658	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	-22.1%	-28,506	-23,354	-20,275	-21,773	-20,758	-7,331	-14,797	-16,614	-18,258	-17,572	-18,256	-17,452	-14,647	-12,854	-12,124	-10,241	-8,287	-	-	-
Share Based Compensation	24.4%	4,368	3,512	4,291	4,650	4,746	4,457	4,390	3,912	4,097	3,732	3,692	3,690	3,347	4,091	1,592	600	482	-	-	100
Cashflow From Investing	35.7%	21,485	15,837	29,420	-3,171	36,929	4,747	-79,114	-109,296	-1,026	-17,835	91,514	-20,951	-20,194	-78,723	-139,069	2,814	4,897	-	-	-
Cashflow From Financing	76600.3%	226,266	295	-	395	1.00	424	2,564	215,945	79.00	2.00	188	255	757	-299	322,012	8,813	-709	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NKTX Income Statement

2024-03-31

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 25,237	$ 26,135
General and administrative	7,525	8,178
Total operating expenses	32,762	34,313
Loss from operations	(32,762)	(34,313)
Other income, net:
Interest income	3,246	3,465
Other (expense) income, net	(2)	33
Total other income, net	3,244	3,498
Net loss	(29,518)	(30,815)
Other comprehensive loss:
Net unrealized (loss) gain on investments	(135)	505
Comprehensive loss	$ (29,653)	$ (30,310)
Net loss per share, basic	$ (0.58)	$ (0.63)
Net loss per share, diluted	$ (0.58)	$ (0.63)
Weighted average shares used to compute net loss per share, basic	50,682,469	48,921,326
Weighted average shares used to compute net loss per share, diluted	50,682,469	48,921,326

NKTX Balance Sheet

2024-03-31

CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 250,285	$ 31,040
Short-term investments	187,109	217,149
Prepaid expenses and other current assets	5,387	4,882
Total current assets	442,781	253,071
Long-term investments	9,814
Restricted cash	2,743	2,743
Property and equipment, net	78,522	79,326
Operating lease right-of-use assets	39,357	39,949
Other long-term assets	3,719	3,796
Total assets	576,936	378,885
Current liabilities
Accounts payable	3,177	3,665
Operating lease liabilities, current portion	6,078	6,069
Accrued and other current liabilities	12,934	13,596
Total current liabilities	22,189	23,330
Operating lease liabilities, net of current portion	81,096	82,270
Total liabilities	103,285	105,600
Commitments and contingencies (Note 7)
Stockholders’ equity
Common stock	7	5
Additional paid-in capital	938,723	708,706
Accumulated other comprehensive (loss) income	(127)	8
Accumulated deficit	(464,952)	(435,434)
Total stockholders’ equity	473,651	273,285
Total liabilities and stockholders’ equity	$ 576,936	$ 378,885

About Nkarta Inc

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

CEO	Mr. Paul J. Hastings
WEBSITE	nkartatx.com
INDUSTRY	Biotechnology
EMPLOYEES	169

Nkarta Inc Frequently Asked Questions

What is the ticker symbol for Nkarta Inc? What does NKTX stand for in stocks?

NKTX is the stock ticker symbol of Nkarta Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nkarta Inc (NKTX)?

As of Fri May 17 2024, market cap of Nkarta Inc is 458.74 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NKTX stock?

You can check NKTX's fair value in chart for subscribers.

What is the fair value of NKTX stock?

You can check NKTX's fair value in chart for subscribers. The fair value of Nkarta Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nkarta Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NKTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nkarta Inc a good stock to buy?

The fair value guage provides a quick view whether NKTX is over valued or under valued. Whether Nkarta Inc is cheap or expensive depends on the assumptions which impact Nkarta Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NKTX.

What is Nkarta Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, NKTX's PE ratio (Price to Earnings) is -3.95 and Price to Sales (PS) ratio is 33.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NKTX PE ratio will change depending on the future growth rate expectations of investors.